Cell-Sheet Engineering for Tissue Repair: Current Perspectives and Clinical Applications

Abstract

Cell-sheet engineering represents a transformative approach in regenerative medicine, enabling the transplantation of contiguous cell layers that maintain their extracellular matrix and cell-cell junctions. This technology is reshaping strategies for tissue repair across various organ systems by facilitating graft integration, enhancing cell survival, and minimizing immune rejection. Recent advances have propelled cell-sheet engineering from preclinical studies to the brink of widespread clinical application, underscoring its importance in modern tissue engineering and regenerative therapies. This review synthesizes contemporary evidence, explores the pathophysiological rationale, discusses practical clinical implications, and highlights emerging trends relevant to medical professionals.

Introduction

Tissue repair and regeneration pose significant challenges in clinical practice, particularly for injuries or diseases where native tissue architecture and function are compromised. Traditional grafting techniques, reliant on single-cell suspensions or scaffold-based constructs, often fail to recapitulate the complex microenvironment necessary for optimal healing. Cell-sheet engineering, first pioneered in the early 2000s, leverages temperature-responsive culture substrates to harvest intact, scaffold-free sheets of cells. These sheets preserve essential structural and functional properties, fostering superior integration and functionality upon transplantation. Over the past decade, cell-sheet engineering has garnered substantial attention in the context of cardiac, corneal, periodontal, and cutaneous tissue repair, reflecting its broad clinical potential.

Epidemiology / Disease Burden

The global burden of tissue loss and dysfunction spans a spectrum of conditions, including ischemic heart disease, chronic wounds, corneal blindness, and periodontitis. According to the World Health Organization, cardiovascular diseases account for an estimated 17.9 million deaths annually, many of which involve irreversible myocardial loss. Chronic non-healing wounds affect up to 2% of the population in developed countries, while corneal injuries and defects contribute to approximately 4.2 million cases of blindness worldwide. The limitations of current reparative strategies highlight an urgent need for innovative cellular therapies such as cell-sheet engineering, which may address unmet clinical needs and improve quality of life for millions of patients.

Pathophysiology

Tissue injury disrupts the structural and functional integrity of affected organs, leading to inflammation, cell death, and fibrotic remodeling. The endogenous repair capacity is often limited by poor vascularization, inadequate cellular migration, and loss of extracellular matrix components. Cell-sheet engineering mitigates these challenges by delivering organized layers of functional cells, which retain their native extracellular matrix and cell-cell adhesions. This configuration not only provides immediate structural support but also promotes paracrine signaling, angiogenesis, and integration with host tissue. Moreover, the absence of exogenous scaffolds reduces the risk of foreign body reactions, further enhancing the clinical safety profile of this approach.

Risk Factors

Risk factors for impaired tissue repair include advanced age, diabetes mellitus, vascular insufficiency, immunosuppression, and chronic inflammation. These conditions hinder cellular proliferation, angiogenesis, and matrix deposition, thereby compromising the efficacy of conventional grafts and increasing susceptibility to graft failure. Cell-sheet engineering offers a promising solution, particularly for patients with such comorbidities, as the technique enhances cell viability and engraftment even in suboptimal microenvironments.

Clinical Features

The clinical manifestations of tissue defects vary by organ system but commonly include pain, functional impairment, and increased risk of infection or further degeneration. For example, myocardial infarction leads to contractile dysfunction and heart failure; chronic wounds manifest as non-healing ulcers; and corneal injuries result in vision loss and photophobia. Cell-sheet therapies aim to restore both structural integrity and function, with reported benefits including improved tissue regeneration, reduced scarring, and enhanced organ performance in preclinical and early clinical studies.

Diagnosis

Accurate diagnosis of tissue injuries requires a combination of clinical evaluation, imaging modalities (e.g., MRI, CT, echocardiography), and histopathological assessment. Biomarkers of injury and healing, such as troponins for cardiac damage or pro-inflammatory cytokines for chronic wounds, aid in identifying candidates for advanced regenerative therapies. Patient selection for cell-sheet engineering is typically guided by the extent of tissue loss, underlying comorbidities, and previous response to standard treatments.

Treatment & Management

Conventional management of tissue defects encompasses surgical repair, autologous or allogeneic grafts, and engineered scaffolds. Cell-sheet engineering introduces a novel paradigm, wherein autologous or allogeneic cells are cultured to confluence on temperature-responsive dishes, harvested as intact sheets, and transplanted onto the defect site. This technique has demonstrated efficacy in cardiac patching post-myocardial infarction, corneal surface reconstruction, periodontal ligament regeneration, and cutaneous wound healing. Key advantages include preservation of cell viability, enhanced paracrine activity, and avoidance of immunogenic scaffold materials. Postoperative management focuses on monitoring for graft adherence, functional restoration, and potential immune responses.

Recent Advances / Emerging Therapies

Innovations in cell-sheet engineering encompass the use of pluripotent stem cells, genetic modification to enhance regenerative potential, and development of multi-layered or composite sheets incorporating vascular or neural elements. Preclinical models have demonstrated improved neovascularization and functional integration, while phase I/II clinical trials in cardiac, ophthalmic, and oral applications report favorable safety and efficacy profiles. Combination strategies, such as the integration of growth factors or bioactive molecules within cell sheets, are being explored to further potentiate reparative outcomes. Additionally, advances in bioreactor technology and automation promise to streamline cell-sheet production, facilitating broader clinical adoption.

Guideline Recommendations

While formal clinical guidelines for cell-sheet engineering remain in development, consensus statements from expert panels emphasize the importance of standardized manufacturing protocols, rigorous preclinical validation, and careful patient selection. Regulatory agencies, including the FDA and EMA, advocate for robust safety monitoring and long-term follow-up in clinical trials. Emerging guidelines are expected to address the integration of cell-sheet therapies into multi-modal treatment algorithms, particularly for patients refractory to conventional interventions.

Conclusion

Cell-sheet engineering represents a paradigm shift in tissue repair, offering a scaffold-free, biologically integrated approach with the potential to address complex clinical challenges across multiple organ systems. Continued translational research, standardized clinical protocols, and collaborative efforts between clinicians, scientists, and regulatory bodies will be essential in realizing the full therapeutic potential of this technology. As evidence accumulates, cell-sheet engineering is poised to become a cornerstone of regenerative medicine, improving outcomes for patients with otherwise intractable tissue defects.